CAL
RMD icon

Capital Analysts LLC’s ResMed RMD Stock Holding History

Capital Analysts LLC’s Portfolio RMD Stock Details RMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-3
Closed -$1K – 1591
2026
Q1 		$1K Buy
+3
New +$748 ﹤0.01% 1521
2015
Q3 		– Sell
-44,051
Closed -$2.48M – 379
2015
Q2 		$2.48M Buy
44,051
+1,843
+4% +$116K 0.51% 50
2015
Q1 		$3.03M Sell
42,208
-6,244
-13% -$406K 0.63% 31
2014
Q4 		$2.72M Buy
48,452
+1,157
+2% +$60.4K 0.6% 34
2014
Q3 		$2.33M Buy
47,295
+2,468
+6% +$126K 0.55% 41
2014
Q2 		$2.27M Buy
44,827
+2,727
+6% +$135K 0.55% 37
2014
Q1 		$1.88M Buy
+42,100
New +$1.89M 0.49% 54

Other funds holding RMD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Capital Analysts LLC's RMD Position: Q2 2026 in Review

Capital Analysts LLC sold out of ResMed (RMD) in Q2 2026, closing a stake of 3 shares — an estimated $1K sold.

Capital Analysts LLC first reported a position in RMD in Q1 2014 and held it in 7 quarters. The position peaked at $3.03M in Q1 2015. 887 funds tracked by Wall St. Rank hold RMD as of Q2 2026.

  • Capital Analysts LLC reported no remaining ResMed position as of Q2 2026 after selling out during the quarter.
  • Capital Analysts LLC sold 3 ResMed shares in Q2 2026, an estimated $1K.
  • Capital Analysts LLC first reported a position in ResMed in Q1 2014 and held it in 7 quarters.
  • Capital Analysts LLC's ResMed position peaked at $3.03M in Q1 2015.
  • 887 funds tracked by Wall St. Rank held ResMed as of Q2 2026.

Based on Capital Analysts LLC's 13F filing for Q2 2026, filed 5 Aug 2026.